Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | KIT |
Variant | W557_E561del |
Impact List | deletion |
Protein Effect | gain of function - predicted |
Gene Variant Descriptions | KIT W557_E561del results in the deletion of five amino acids in the juxtamembrane domain (exon 11) of the Kit protein from amino acids 557 to 561 (PMID: 16226710). W557_E561del has not been characterized, however similar Kit exon 11 deletions are activating (PMID: 9438854, PMID: 15365079), and therefore, is predicted to lead to a gain of Kit protein function . |
Associated Drug Resistance | |
Category Variants Paths |
KIT mutant KIT act mut KIT exon 11 del KIT W557_E561del KIT mutant KIT exon11 KIT exon 11 del KIT W557_E561del |
Transcript | NM_000222.3 |
gDNA | chr4:g.54727437_54727451del15 |
cDNA | c.1669_1683del15 |
Protein | p.W557_E561delWKVVE |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |
Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
---|---|---|---|---|---|
NM_001093772 | chr4:g.54727449_54727463del15 | c.1669_1683del15 | p.E557_G561delEEING | RefSeq | GRCh38/hg38 |
XM_005265742.3 | chr4:g.54727447_54727461del15 | c.1670_1684del15 | p.V557_N561delVEEIN | RefSeq | GRCh38/hg38 |
XM_017008179.1 | chr4:g.54727447_54727461del15 | c.1670_1684del15 | p.V557_N561delVEEIN | RefSeq | GRCh38/hg38 |
XM_017008178.1 | chr4:g.54727437_54727451del15 | c.1669_1683del15 | p.W557_E561delWKVVE | RefSeq | GRCh38/hg38 |
NM_001385290.1 | chr4:g.54727434_54727448del15 | c.1669_1683del15 | p.Q557_V561delQWKVV | RefSeq | GRCh38/hg38 |
XM_005265740.1 | chr4:g.54727434_54727448del15 | c.1669_1683del15 | p.Q557_V561delQWKVV | RefSeq | GRCh38/hg38 |
XM_017008179 | chr4:g.54727447_54727461del15 | c.1670_1684del15 | p.V557_N561delVEEIN | RefSeq | GRCh38/hg38 |
NM_001385284.1 | chr4:g.54727434_54727448del15 | c.1669_1683del15 | p.Q557_V561delQWKVV | RefSeq | GRCh38/hg38 |
NM_001385292.1 | chr4:g.54727447_54727461del15 | c.1670_1684del15 | p.V557_N561delVEEIN | RefSeq | GRCh38/hg38 |
NM_000222.3 | chr4:g.54727437_54727451del15 | c.1669_1683del15 | p.W557_E561delWKVVE | RefSeq | GRCh38/hg38 |
XM_017008178 | chr4:g.54727437_54727451del15 | c.1669_1683del15 | p.W557_E561delWKVVE | RefSeq | GRCh38/hg38 |
NM_001093772.1 | chr4:g.54727449_54727463del15 | c.1669_1683del15 | p.E557_G561delEEING | RefSeq | GRCh38/hg38 |
NM_000222.2 | chr4:g.54727437_54727451del15 | c.1669_1683del15 | p.W557_E561delWKVVE | RefSeq | GRCh38/hg38 |
NM_001385286.1 | chr4:g.54727449_54727463del15 | c.1669_1683del15 | p.E557_G561delEEING | RefSeq | GRCh38/hg38 |
XM_005265742 | chr4:g.54727447_54727461del15 | c.1670_1684del15 | p.V557_N561delVEEIN | RefSeq | GRCh38/hg38 |
XM_005265741.1 | chr4:g.54727434_54727448del15 | c.1669_1683del15 | p.Q557_V561delQWKVV | RefSeq | GRCh38/hg38 |
NM_001093772.2 | chr4:g.54727449_54727463del15 | c.1669_1683del15 | p.E557_G561delEEING | RefSeq | GRCh38/hg38 |
NM_001385285.1 | chr4:g.54727437_54727451del15 | c.1669_1683del15 | p.W557_E561delWKVVE | RefSeq | GRCh38/hg38 |
NM_000222 | chr4:g.54727437_54727451del15 | c.1669_1683del15 | p.W557_E561delWKVVE | RefSeq | GRCh38/hg38 |
XM_005265741 | chr4:g.54727434_54727448del15 | c.1669_1683del15 | p.Q557_V561delQWKVV | RefSeq | GRCh38/hg38 |
NM_001385288.1 | chr4:g.54727447_54727461del15 | c.1670_1684del15 | p.V557_N561delVEEIN | RefSeq | GRCh38/hg38 |
XM_005265740 | chr4:g.54727434_54727448del15 | c.1669_1683del15 | p.Q557_V561delQWKVV | RefSeq | GRCh38/hg38 |
XM_017008180 | chr4:g.54727449_54727463del15 | c.1669_1683del15 | p.E557_G561delEEING | RefSeq | GRCh38/hg38 |
XM_017008180.1 | chr4:g.54727449_54727463del15 | c.1669_1683del15 | p.E557_G561delEEING | RefSeq | GRCh38/hg38 |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
KIT W557_E561del | gastrointestinal stromal tumor | sensitive | Imatinib | Case Reports/Case Series | Actionable | In a clinical case study, Gleevec (imatinib) treatment led to partial responses in two patients with gastrointestinal stromal tumors harboring KIT W557_E561del, with a progression-free survival (PFS) of 10.7 mo and overall survival (OS) of 14.9 mo in one patient, and a PFS of 32.2 mo and OS of 34.4 mo in the second patient (PMID: 18294292). | 18294292 |
KIT W557_E561del | gastrointestinal stromal tumor | sensitive | Imatinib | Preclinical - Pdx | Actionable | In a preclinical study, Gleevec (imatinib) inhibited tumor growth in a patient-derived xenograft (PDX) model of gastrointestinal stromal tumor harboring KIT W557_E561del with overexpression of GPR20 (IHC score 3+) (PMID: 33579785). | 33579785 |
KIT W557_E561del | gastrointestinal stromal tumor | sensitive | Sunitinib | Preclinical - Pdx | Actionable | In a preclinical study, Sutent (sunitinib) inhibited tumor growth in a patient-derived xenograft (PDX) model of gastrointestinal stromal tumor harboring KIT W557_E561del with overexpression of GPR20 (IHC score 3+) (PMID: 33579785). | 33579785 |